Adenocarcinoma of the Distal Bile Duct

  title={Adenocarcinoma of the Distal Bile Duct},
  author={Luca Bortolasi and Lawrence J. Burgart and Gregory G. Tsiotos and Enrique Luque-de Le{\'o}n and Michael G Sarr},
  journal={Digestive Surgery},
  pages={36 - 41}
Background/Aims: Primary distal bile duct adenocarcinomas (DBDAs) are unusual neoplasms, necessitating pancreaticoduodenectomy for cure. The aims of this study were to evaluate the prognostic importance of lymphatic and perineural invasion, long-term outcome of patients after resection, and differences in outcome with hilar cholangiocarcinoma and pancreatic carcinoma. Methods: The medical records and histopathological slides of 15 patients (8 men and 7 women) with documented DBDA after curative… 

Tables from this paper

Distal Bile Duct Carcinoma: Prognostic Factors After Curative Surgery. A Series of 112 Cases

Overexpression of p53 in DBDC is strongly associated with significantly reduced survival, independently of clinicopathological prognostic factors, and longer operative time may have unfavorable effect on prognosis of patients with DBDC.

Adenosquamous carcinoma of the extrahepatic biliary tract: clinicopathological analysis of Japanese cases of this uncommon disease

Curative surgical resection for adenosquamous carcinoma remains the only effective treat-ment, because it offers the chance of long-term survival, and new adjuvant strategies are required for improvements in patient outcomes.

The short- and long-term outcomes of pancreaticoduodenectomy for distal cholangiocarcinoma.

Vascular resection is the most important negative prognostic factor for long-term survival in distal cholangiocarcinoma patients and the main factor directly influencing the survival of DCC patients is surgical complications.

Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma.

Gallbladder and/or CD invasions did not affect survival rates of patients with DBDC, while pancreatic and duodenal invasions affected survival rates, and differences in survival rates may originate from the different invasive patterns of DBDCs.

Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution

R0 resection remains the best chance for long-term survival, and lymph node status is the most important prognostic factor following R1 resection, according to a large series of patients with bile duct cancer.

Survival and an overview of decision-making in patients with cholangiocarcinoma.

In few patients with a resectable cholangiocarcinoma, an explorative laparotomy is often necessary to evaluate resectability, however, long-term survival is significantly better in patients who received radical surgical resection.

Impact of Reconstruction Methods on Outcome of Pancreatoduodenectomy in Pancreatic Cancer Patients

The Billroth II reconstruction may have some advantages over the Billroth I reconstruction in terms of postoperative oral ingestion and avoiding bypass surgery and PTCD at the time of recurrence.

Outcome of surgical resection in Klatskin tumors.

Surgical resection continues to be the main treatment of HCC and negative resection margins achieved with major hepatic resections are associated with improved outcome, and improvements in adjuvant therapy are essential for improving long-term outcome.

Surgical resection of liver metastasis in pancreatic and periampullary carcinoma.

Perioperative chemotherapy is the cornerstone of treatment in patients with liver metastasis from pancreatic and periampullary carcinoma and Liver resection from early liver metastases could be acceptable in selected patients with oligometastatic disease and small single lesions taking into account the individual risk of complications.



Cholangiocarcinoma: clinical significance of tumor location along the extrahepatic bile duct.

Patients with proximal cancer should undergo resection, and RT may not be needed, and expectations should be limited, according to criteria for resection and/or radiation therapy of extrahepatic bile duct cancer.

Outcome of treatment for distal bile duct cancer

By univariate and multivariate analysis, resectability and negative node status were the only predictors of favourable outcome, and patients having resection of pancreatic adenocarcinoma with distal bile duct tumours have a better outlook.

Radical resection for carcinoma of the ampulla of Vater.

Radical resection for ampullary cancer can be performed with a low morbidity and mortality and should remain the procedure of choice for Ampullary carcinoma.

Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving?

Five-year survival for patients undergoing pancreatic resection for lesions deemed to be clinically “curable” intraoperatively and histologically reviewed/confirmed to be ductal adenocarcinoma of the pancreas is approximately 7%.

Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience.

Prognosis for patients with ICC remains poor; resection, though, appears to prolong survival; no pathologic condition was found to be associated with the development of ICC and overall survival correlated with stage of the tumor.

Outcomes after curative resections of cholangiocarcinoma.

Although the tumor extent and the patient's overall health will affect outcome, curative resection for cholangiocarcinoma at all sites should be undertaken since this treatment offers the best chance for long-term survival.

Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Cholangiocarcinoma is best classified into three broad groups: 1) intrahepatic, 2) perihilar, and 3) distal tumors, which correlate with anatomic distribution and imply preferred treatment.

Carcinoma of the Extrahepatic Bile Ducts The University of California at San Francisco Experience

The mainstay of bile duct carcinoma management was maximal surgical resection in these patients and postoperative radiotherapy gave patients with positive microscopic margins a significant survival advantage and may be of value in selected patients with gross disease.